Clinical Trial Search

Primary: NK Cell Activation — 19; 20; 4; 3 percentage of activity

Primary: Cerebral Non-invasive Near Infrared Spectroscopy (NIRS) — 0.05 percentage change per minute

Primary: Change From Baseline in Percentage of Glycated Hemoglobin (HbA1c) — -0.94; 0.00 percentage of HbA1c — p=<0.001

Primary: The Presence of MRSA on Repeated Swabs to Assess the Efficacy of These Medications on Clearing MRSA Colonization — 12; 14; 0 Participants

Primary: Median Change in Upper Extremity Fugl Meyer Assessment Score — 4.5; 6.0; 4; 6 scores on a scale — p=0.256

Primary: Feasibility as Assessed by Proportion of Patients Eligible for Intermittent Therapy Who Actually Receive it — 20 Participants

Primary: Change From Baseline in Percentage of Glycated Hemoglobin (HbA1c) — -0.97; -0.10 percentage of HbA1c — p=<0.001

Primary: Object Location Touchscreen Task (Version C) Free Recall Total Error — 121.498; 99.77 centimeters — p=.300

Primary: Local Anesthetic Supplementation (Frequency) — 11; 7 participants — p=0.236

Primary: Median Progression-free Survival — 5 months

Primary: Clinician Assessed Duration of the Classical Herpetic Lesion — 162.7; 163.6 hours

Primary: Time-weighted Sum of Pain Relief and Pain Intensity Difference Scores From 0 to 12 Hours After the First Dose (SPRID 0-12) — 18.2; 41.5 units on a scale — p=<0.001

Primary: Change in Average AM and PM Subject-reported 12-hour Reflective Total Nasal Symptoms Score (rTNSS) From Baseline to End of Treatment. — 10.1; 10.3; 10.2; 10.2 units on a…

Primary: Quit Status — 0.5; 0.2; 0.7; 0.5 number of days quit

Primary: Progression Free Survival (PFS) — 6.6; 7.5; 7.6 months